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RESEARCH ARTICLE Open Access
A cluster randomised control trial to
evaluate the effectiveness and cost-
effectiveness of the Italian medicines use
review (I-MUR) for asthma patients
Andrea Manfrin1*, Michela Tinelli2, Trudy Thomas1 and Janet Krska1
Abstract
Background: The economic burden of asthma, which relates to the degree of control, is €5 billion annually in Italy.
Pharmacists could help improve asthma control, reducing this burden. This study aimed to evaluate the
effectiveness and cost-effectiveness of Medicines Use Reviews provided by community pharmacists in asthma.
Methods: This cluster randomised, multi-centre, controlled trial in adult patients with asthma was conducted in 15
of the 20 regions of Italy between September 2014 and July 2015. After stratification by region, community
pharmacists were randomly allocated to group A (trained in and delivered the intervention at baseline) or B
(training and delivery 3 months later), using computerised random number generation in blocks of 10. Each
recruited up to five patients, with both groups followed for 9 months.
The intervention consisted of a systematic, structured face-to-face consultation with a pharmacist, covering asthma
symptoms, medicines used, attitude towards medicines and adherence, recording pharmacist-identified pharmaceutical
care issues (PCIs). The primary outcome was asthma control, assessed using the Asthma-Control-Test (ACT)
score (ACT ≥ 20 represents good control). Secondary outcomes were: number of active ingredients, adherence,
cost-effectiveness compared with usual care. Although blinding was not possible for either pharmacists or
patients, assessment of outcomes was conducted by researchers blind to group allocation.
Results: Numbers of pharmacists and patients enrolled were 283 (A = 136; B = 147) and 1263 (A = 600; B = 663),
numbers completing were 201 (A = 97; B = 104) and 816 (A = 400; B = 416), respectively. Patients were similar in
age and gender and 56.13% (458/816) had poor/partial asthma control. Pharmacists identified 1256 PCIs (mean
1.54/patient), mostly need for education, monitoring and potentially ineffective therapy. Median ACT score at
baseline differed between groups (A = 19, B = 18; p < 0.01). Odds ratio for improved asthma control was 1.76
(95% CI 1.33–2.33) and number needed to treat 10 (95% CI 6–28). Number of active ingredients reduced by 7.9%
post-intervention (p < 0.01). Adherence improved by 35.4% 3 months post-intervention and 40.0% at 6 months
(p < 0.01). The probability of the intervention being more cost-effective than usual care was 100% at 9 months.
Conclusions: This community pharmacist-based intervention demonstrated both effectiveness and cost-
effectiveness. It has since been implemented as the first community pharmacy cognitive service in Italy.
Trial registration: TRN: ISRCTN72438848 (registered 5th January 2015, retrospectively).
Keywords: Asthma control, Medicines use review, Community pharmacy, Effectiveness, Cost-effectiveness
* Correspondence: a.manfrin@kent.ac.uk
1Medway School of Pharmacy, Universities of Greenwich and Kent at
Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent
ME4 4TB, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Manfrin et al. BMC Health Services Research  (2017) 17:300 
DOI 10.1186/s12913-017-2245-9
Background
The prevalence of asthma has been increasing since the
late 1990’s and it has been estimated that about 400 million
people will suffer from asthma by 2025 [1, 2]. Currently the
number of disability-adjusted life years (DALYs) lost to lack
of control of asthma worldwide translates into a global loss
of 15 million DALYs per year and an estimated one in every
250 deaths worldwide is caused by asthma. Asthma ac-
counts for an economic loss of €72 billion annually in the
28 countries of the EU [3]; this includes the annual costs of
health care (about €20 billion), the loss of productivity for
patients (€14 billion), and a monetised value of DALYs lost
of €38 billion. In the UK the burden of asthma was esti-
mated at a cost to the NHS of more than £1 billion/year, in-
cluding prescribing, hospital admissions and primary care
consultations [4, 5]. In Italy the latest estimate showed an
asthma prevalence of 6.2% [6] with an economic loss of €5
billion annually. An Italian cost of illness study, published
in 2000, reported a mean annual cost for an asthmatic pa-
tient of €741 (95% CI: 599–884), ranging from €379 (95%
CI: 216–541) for well-controlled asthmatics to €1,341 (95%
CI: 978–1,706) for poorly controlled cases, the latter ac-
counting for 46.2% of the total cost of asthma [7]. In 2006
the Global Initiative for Asthma (GINA) advocated a new
asthma management approach, based on asthma control
rather than asthma severity [8], since “the principal object-
ive of asthma treatment is to achieve asthma control”. The
GINA 2015 pocket guide for asthma management and pre-
vention [9] defines asthma control as the extent to which
the effects of asthma can be seen in patients, or has been
reduced or removed by treatment. While guidance on
asthma control abounds in the UK [10, 11] and other coun-
tries, [12] many patients do not achieve good asthma con-
trol, with negative implications for their health and quality
of life, as well as increased health care costs and loss of
productivity [6, 13, 14]. Asthma control may be affected by
co-morbidity, continued exposure to triggers, behavioural
issues, patient preferences, ineffective treatment, poor ad-
herence and costs for patients [15].
Pharmaceutical care, defined in Europe [16] as “‘the
pharmacists’ contribution to the care of individuals in
order to optimise medicines use and improve health out-
comes”, could contribute to asthma management. Many
studies report positive effects of pharmacist interven-
tions in asthma [17–28]. Indeed, a systematic review
published in 2016 [29] looking at the impact of pharma-
cists’ intervention on clinical outcomes in asthma identi-
fied 21 studies. However of these, only nine adopted a
randomised control or a cluster randomised control de-
sign, only ten measured asthma control as main out-
come as suggested by GINA management approach in
assessing effectiveness, [9] and only one included an
economic evaluation of the pharmacy intervention [22].
Pharmacy-led approaches to asthma management include
both one-off interventions, such as Medicines Use Review
(MUR), and longer-term provision of pharmaceutical care.
In England, the MUR is a cognitive pharmaceutical ser-
vice, funded by the government, [30] where accredited
pharmacists can undertake structured adherence-centred
reviews with patients using multiple medicines, particu-
larly those receiving medicines for asthma and other long-
term conditions. Similar services exist in some European
(Denmark, Switzerland) and other countries (Australia,
Canada, New Zealand, USA) [31], whereas in Italy such
services (for asthma or other conditions) have not been
introduced. Therefore, no empirical research exists ad-
dressing the effectiveness or cost-effectiveness of a MUR
service in Italy.
This study describes the first attempt to deliver a novel
community pharmacy intervention for asthma patients,
adapted from the MUR service for chronic diseases in
England, across the Italian territory and to evaluate its
effectiveness and cost-effectiveness. The key research
questions were:
Is the Italian Medicines Use Review (I-MUR) service
provided by community pharmacists:
i. Effective in
a. Improving asthma control as assessed by the
Asthma Control Test (ACT) score?
b. Optimising the number of medicines (active
ingredients) used by patients?
c. Identifying pharmaceutical care issues?
d. Improving patients’ adherence to asthma
medications?
ii. Cost-effective for the healthcare system and the
society (compared with usual care) in terms of cost
per quality adjusted life year gained?
Methods
The study was a cluster randomised controlled trial, with
phased intervention, as defined by Gums et al. (2016) [32],
in order to avoid selection bias, with control clusters pro-
viding the intervention after the primary end point (primary
outcome) was finished (T3). Therefore all pharmacists
(intervention and control) provided the I-MUR service to
patients with asthma, but at different time points during
the study. The study protocol is published elsewhere [33].
Community pharmacists were recruited from 15 out
of the 20 Italian regions: Trentino Alto Adige, Lombardia,
Sicilia, Puglia, Sardegna, Piemonte, Valle d’Aosta, Veneto,
Friuli Venezia Giulia, Toscana, Emilia Romagna, Marche,
Abruzzo, Lazio and Campania. It was conducted between
September 2014 and July 2015 with data collection at
3-months intervals (at baseline (T0); at 3 months (T3);
at 6 months (T6); at 9 months (T9)). Pharmacists were
randomly allocated to two groups after stratification by
region: group A were trained to provide the I-MUR
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immediately after completion of the baseline ACT score
at T0; group B received training and provided this ser-
vice 3 months later, at T3.
Intervention
The I-MUR consisted of a systematic, structured inter-
view, conducted in a private room within the pharmacy,
which covered asthma symptoms, medicines used, atti-
tudes towards medicines and adherence. The pharma-
cists were trained to identify pharmaceutical care issues
(PCIs) which could impact on optimal medicines use or
asthma control and provide advice to the patients and
recommendations to their GP, as necessary. As a process
measure, the number of PCIs identified by pharmacists
during the I-MUR service provision, classified using the
method of Krska et al [34], were recorded.
Outcome measures
Primary outcome measure: Asthma control at baseline
(T0) and at 3-months intervals (T3, T6 and T9), assessed
using the ACT score. This measure has previously been
used in Italy, in a study conducted by the Italian Society
of General Medicine (Societá Italiana di Medicina Gen-
erale) [35]. It was defined by international guidelines as:
ACT ≤ 14 = not controlled, 15 ≤ACT ≤ 19 = partially con-
trolled, and ACT ≥ 20 controlled [36]. A clinically relevant
difference was defined as change from not controlled/par-
tially controlled to controlled asthma.
Secondary outcome measures were:
1. Number of active ingredients used by patients at the
point of delivery of the I-MUR provision and 3-months
follow-up, as reported by patients.
2. Patients’ self-reported adherence to asthma medication
at the point of delivery of the I-MUR provision and
3-months follow-up, measured using two questions
adapted from the Morisky Medication-Adherence
Scale-MMAS (8-item) [37] embedded within the
I-MUR interview.
3. Cost-effectiveness of I-MUR asthma service compared
with usual care, measured in terms of cost per QALY
(as a measure of disease burden, including both the
quality and the quantity of life) gained, at different
time points.
Recruitment, inclusion criteria, randomization and blinding
The study was conducted with the support of the Italian
Pharmacists’ Federation (FOFI), which supported pharma-
cist recruitment in each region. Eligible pharmacists, work-
ing in pharmacies with private consultation facilities and
internet connection, were identified by FOFI and invited to
participate in the study. Those who agreed received training
in providing the I-MUR, patient recruitment and data col-
lection by AM. Each pharmacist was instructed to recruit
five adult patients with an asthma diagnosis or at least 6
months consecutive use of medicines indicating asthma.
Pharmacists within each region were randomly allocated
to Group A (intervention) or B (control) by JK, using com-
puterised random number generation in blocks of 10. AM
provided training at either T0 (Group A) or T3 (Group B),
thus neither the research team nor the pharmacists were
blind to delivery of the intervention. All data, comprising
both primary and secondary outcome measures, were col-
lected by the pharmacists and entered anonymously onto
a web-based template, to which the researchers remained
blind until an interim analysis took place at T6, which was
required by the funders.
Sample size, training and study-timeline
The study aimed to involve 360 pharmacists and 1800
patients, with each pharmacist recruiting five patients.
Full inclusion and exclusion criteria for both pharma-
cists and patients are described in the trial protocol, [33]
along with details of the training provided to pharmacists
and the study timeline.
Neither the pharmacist nor patient numbers anticipated
were achieved, therefore it was necessary to determine the
post-hoc power of the study. In the light of the number of
pharmacists and patients enrolled and remaining in the
study from T0 to T9, (see results), the actual power of the
study was calculated maintaining the intra-cluster correl-
ation coefficient (ICC) value of 0.02 and level of signifi-
cance (two-tailed alpha) at 0.05 as originally proposed
(SPSS Sample Power 3, IBM) [38].
Data sources
ACT score was obtained at all four time points, adherence
and number of active ingredients on three occasions and
PCIs once; more detail is available in the protocol.
Due to budget constraints primary data on cost and
utility outcomes were not collected. Evidence on direct
and indirect costs [6, 13] and health benefit (e.g. utility
assessed using EuroQol 5 dimensions, EQ-5D) [39] was
extrapolated from the literature and used to inform the
economic evaluation (see below).
Effectiveness analysis
Effectiveness data on asthma control, number of active
ingredients used, number of PCIs, patients’ adherence to
asthma medication were visually inspected using the
quantile-quantile plot and the Kolmogorov-Smirnov test
to check for normality. Data were not normally distrib-
uted therefore non-parametric techniques were used for
analysis. Differences between groups A and B were com-
pared using Mann-Whitney U test for continuous variables
and X2 (Chi square) for categorical variables. Wilcoxon Sign
Rank Test was used for continuous variables within the
same group at different time points (T0, T3, T6 and T9)
Manfrin et al. BMC Health Services Research  (2017) 17:300 Page 3 of 13
[40]. Variation of ACT score across T0, T3, T6 and T9 was
conducted using Friedman’s ANOVA, instead of one way
repeated measure ANOVA as anticipated in the protocol.
Correspondence analysis (CA), a multivariate analysis tech-
nique which allows graphical representation of data showing
how variables are related, was used to assess the relationship
between ACT scores and adherence. The primary outcome
(ACT score) was analysed using two separate approaches:
intention to treat (ITT) analysis, applying the last observa-
tion carried forward (LOCF), and per protocol analysis (PP).
A separate analysis of primary outcome at T3, using gener-
alised estimating equations (GEE), was conducted as recom-
mended by Consort Statement 2010 [41] and Galbraith et
al. (2010) [42] for cluster data, because GEE is a semipara-
metric technique used for continuous non-normal, binary
and categorical responses. Moreover the Agency for Health-
care Research and Quality (AHRQ) suggests using GEE to
either repeated measures at fixed intervals or for a single
measure accounting for the clustering effect (multi-site
study) as in our case [43]. Binary logistic analysis was used,
dichotomising outcomes into not-controlled (ACT ≤ 19)
and controlled (ACT ≥ 20). The GEE model was adjusted
for the ACT score at baseline using age and gender. The
relative risk (RR), the relative risk reduction (RRR), the abso-
lute risk reduction (ARR) and the number needed to treat
(NNT) were calculated using the PP results. An online cal-
culator provided by the Centre for Evidence-Based Medi-
cine of Toronto was used to confirm the results calculated
manually, which also provided significance levels (p value)
and 95% confidence intervals (CI) [44].
Secondary outcomes (number of active ingredients used,
number of PCIs, adherence) were analysed only for patients
completing the trial (PP). All analyses were conducted
using SPSS software v22.
Cost effectiveness analysis
Published data from European [6, 13] and Italian
population-based studies monitoring the annual cost [6]
and quality of life [39] in terms of EQ-5D relating to ACT
score were used for this analysis. Average annual cost and
utility estimates per patient were extrapolated for not con-
trolled, partially controlled, and controlled patients (see
ACT score categories above) and linked to the individual
patient ACT scores reported at all four time points (T0, T3,
T6, and T9). Group B patients were defined as receiving
usual care by keeping ACT scores measured at T3 (prior to
receiving the I-MUR service) constant across time. A sensi-
tivity analysis was conducted keeping Group B ACT scores
at T3 constant across time (T6, T9). As mean ACT score
values differed between the groups at baseline, changes in
costs and QALY over the follow-up period considering
three separate scenarios, (T3, T6 and T9) were analysed.
The primary economic analysis compared I-MUR ser-
vice and usual care from the public healthcare perspective
whereas the secondary analysis considered both direct and
indirect costs. For the primary analysis we used Vervloet
et al. (2006) [13] cost data on scheduled healthcare visits
to their usual physician and specialist, unscheduled health-
care asthma related in-patient admissions, emergency
visits, and emergency contacts with a physician. The sec-
ondary analysis included indirect costs on productivity
losses (working days lost) and leisure time forgone (days
with limited, not work-related activities) as well as direct
costs on doctor visits, clinical and laboratory tests,
pharmacological treatment, emergency visits, and hospital
admissions, using data from Accordini et al. (2013) [6].
Costs were actualised to 2015 values using the appropriate
consumer price index [45]. The cost for delivering the I-
MUR service to Group A at T0 was €40, calculated based
on data available in the international literature [31].
The summary cost-effectiveness statistic calculated was
the incremental cost-effectiveness ratio (ICER). Uncer-
tainty and variation around the ICER mean are repre-
sented by the cost effectiveness acceptability curve
(CEAC), obtained by re-sampling the data 1000 times
to generate a mean cost and life year or QALY gain
from each group, using a nonparametric bootstrap ap-
proach. The proportion of re-sampled datasets for
which the calculated ICER lies below a given threshold
is interpreted as the probability that the ICER of the
intervention is below that threshold. Due to the lack of
an official willingness-to-pay (WTP) threshold in Italy,
we used a threshold of €30,000 (£24,017) per QALY,
which is within the values recognized by the National
Institute for Health and Care Excellence range of ac-
ceptable cost effectiveness (£20,000–30,000 per QALY).
Data analysis was performed using STATA v 13.
Results
There were 360 pharmacists randomised, of whom 283
started the study, recruiting 1263 patients at T0, with 201
pharmacists and 816 patients completing the study and
having data at each time point. The median number of pa-
tients enrolled by each pharmacist was four. The overall
drop-out rate from T0 to T9 was 29% (n = 82) for pharma-
cists and 35% (n = 447) for patients. The numbers in each
group at T9 were 400 (49% of the total) in group A and
416 (51%) in group B (Fig. 1). Based on a 20% increase in
the proportion of patients with controlled asthma (ACT
score ≥20), considering the number of individuals per clus-
ter (4), the ICC (0.02), the calculated design effect (DE) was
1.06, which provided an effective sample size of 758 pa-
tients, and the power attained by the study was 90%.
Baseline characteristics
The numbers of pharmacists and patients from the 15
regions differed, but patient numbers recruited to Groups
A and B within each region was similar. The highest
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number of patients was found in Sardinia and the low-
est in Lazio-Campania. At T0, age range and gender
showed no statistical difference between the two groups
(Table 1). Overall there was a majority of female pa-
tients in both the PP (58.82%; n = 480) and ITT analysis
(57.17%; n = 722).
Process measure: pharmaceutical care issues (PCIs)
Pharmacists identified PCIs while providing the I-MUR
intervention in 527 (64.58%) patients; 277 (69.25%) of
Group A patients and 250 (60.00%) of Group B patients.
The total number of PCIs identified was 1256, mean for
the total population 1.54 per patient, and among patients
with PCIs 2.40. Education required was the most frequent
PCI identified in both groups, which together with moni-
toring issues, discrepancy between dose prescribed and
dose used, potentially ineffective therapy and potential ad-
verse reactions accounted for 64.70% of all PCIs identified.
Primary outcome: asthma control
Using a per protocol approach to analysis, the overall
proportion of patients with poorly controlled asthma at
baseline (T0) was 56.13% (458/816). However median
ACT score differed significantly between the two groups,
being lower in Group B patients, due to a higher propor-
tion having poor asthma control, compared to Group A
patients (Table 1). At T3, asthma control in Group A pa-
tients, who had received the I-MUR intervention, showed
both a statistically significant difference (p < 0.01) and a
clinically relevant difference compared with baseline, with
the median ACT score increasing from 19 (uncontrolled)
to 20.50 (controlled) (Table 2). There were 41 of 205 pa-
tients (20.00%) with ACT score ≤20 who achieved control,
and the proportion of patients with controlled asthma in-
creased from 48.70 to 59.00% (Fig. 2). Group B patients,
who continued to receive usual care and did not receive
the I-MUR intervention until after the ACT score was ob-
tained at T3, also had a statistically significant increase in
ACT score (p < 0.01); 25/283 (9.90%) with poor or partial
control achieved good control; the median ACT score
increased from 18 to 19 (Table 2) and the proportion of
patients with controlled asthma increased from 39.30
to 45.20% (Fig. 2). However, as the median ACT score
in Group B at T3 was still below the threshold for good
Fig. 1 CONSORT diagram describing the flow of participants though the study
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control (ACT ≥20), this may not be regarded as a clin-
ically relevant change. The proportional increase in
asthma control from T0 to T3 was 21% in Group A
and 15% in Group B, the RR was 2, the RRR was 1.02
(95% CI 2.21–0.28), the ARR was 0.10 (95% CI 0.17–0.03)
and the NNT was 10 (95% CI 6–28). At T6, asthma con-
trol improved further in both groups. The increase in
Group B patients, 3 months after receiving the I-MUR
intervention, was both statistically significant (p < 0.01)
and clinically significant median ACT score increasing
from 19 (not controlled) to 20 (controlled) (Table 2). The
proportion of Group B patients controlled increased again
at T9, although the median ACT score remained the same
(p = 0.05). Patients in Group A continued to show im-
provements in ACT score both at T6 (ACT = 21) and T9
(ACT = 22), but only the improvement at T9 was statisti-
cally significant (p < 0.01).
Using this approach, the proportion of patients in both
groups with controlled asthma continued to improve at
each time point, but the median ACT score only reached
a value indicating controlled asthma in both groups follow-
ing the I-MUR intervention. The increase was greater in
group B (29.00%) compared to group A (21.00%) (p < 0.01).
From T0 to T9 the percentage increase in controlled pa-
tients was 40.20% and 45.00% respectively in Groups A and
B. Thus asthma control was not only sustained but contin-
ued to increase throughout the study (Fig. 2).
Including all patients in an ITT analysis showed an
even greater difference between the groups at baseline in
the proportion with asthma control (ACT score ≥20)
and that the median ACT score did not reach ≥20 for
patients in Group B until T9, whereas patients in Group
A achieved this at T3. However, as with the per protocol
analysis, ACT score showed an overall increase in both
groups at each time point (p < 0.01; Friedman’s ANOVA).
The result of the GEE analysis applied to PP showed that
the I-MUR intervention resulted in improved asthma con-
trol (ACT scores at T0 versus ACT scores at T3): patients
receiving the intervention were 1.8 times more likely to
improve from not controlled (ACT ≤ 19) to controlled
(ACT ≥ 20) than control patients (odds ratio (OR) 1.76,
95% CI 1.33–2.33); the ICC was 0.07 (95% CI 0.008–
0.168). A similar result was obtained also when a more
stringent and conservative approach was used during the
ITT analysis (OR 1.70, 95% CI 1.36–2.13).
Secondary outcomes
Number of active ingredients
Data on asthma-related medicines regularly used by
patients were gathered during the I-MUR intervention, at
Table 2 Median ACT scores plus inter quartile range (IQR) for
Group A and Group B using both PP and ITT analyses
T0 T3 T6 T9
PP GA 19 (15–23) 20.5 (17–23) 21 (17–24) 22 (18–24)
GB 18 (14–22) 19 (15–22) 20 (16–22.75) 20 (16–23)
ITT GA 19 (14.25–23) 20 (16–23) 21 (16–23) 21 (17–24)
GB 17 (17–21) 18 (14–21) 19 (15–22) 20 (15–22)
Intervention was delivered immediately after ACT at T0 in Group A and
immediately after ACT at T3 in Group B, thus T6 scores are 6- and 3-months
post-intervention for groups A and B respectively; T9 scores are 9- and
6-months post-intervention for groups A and B
Table 1 Baseline characteristics and ACT scores
Recruited Completed
Group A Group B p Group A Group B p-value
Number of patients 600 663 400 416
Female %** 58.80 55.70 0.26 59.80 57.90 0.60
Age range n (%)
18 to 30** 55 (9.17) 68 (10.26) 0.96 32 (8.00) 43 (10.34) 0.69
31 to 40** 81 (13.50) 89 (13.42) 0.96 58 (14.50) 62 (14.90) 0.69
41 to 50** 117 (19.50) 122 (18.40) 0.96 79 (19.75) 77 (18.51) 0.69
51 to 60** 114 (19.00) 125 (18.85) 0.96 73 (18.25) 80 (19.23) 0.69
61 to 70** 125 (20.83) 136 (20.51) 0.96 82 (20.50) 77 (18.51) 0.69
71 to 80** 83 (13.83) 88 (13.27) 0.96 59 (14.75) 52 (12.50) 0.69
Over 81** 25 (4.17) 35 (5.28) 0.96 17 (4.25) 25 (6.01) 0.69
ACT scores
Median (IQR)* 19 (14.25–23) 17 (17–21) <0.01 19 (15–23) 18 (18–24) <0.01
5–14 not controlled n(%)** 150 (25.00) 203 (30.60) <0.01 91 (22.80) 121 (29.10) 0.01
15–19 partially controlled n(%)** 177 (29.50) 223 (33.60) <0.01 114 (28.50) 132 (31.60) 0.01
20–25 controlled n(%)** 273 (45.50) 237 (35.71) <0.01 195 (48.70) 163 (39.30) 0.01
* Mann-Whitney U test, Median (IQR), p < 0.05
**Chi-square test, p < 0.05
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T0 for group A and at T3 for group B. There were no
significant statistical differences between the two
groups. The total number of active ingredients re-
corded by pharmacists as being used in 812 patients
was 4310, median 5 per patient, range 0 - >20. After
the I-MUR intervention, the total number of active in-
gredients was 3970 (n = 759), median 4, range 1 – 20,
a reduction of n = 340 or 7.90% (p < 0.01). The reduc-
tion was maintained in both groups 6 months after the
intervention (Table 3).
Adherence
Self-reported adherence was recorded in 802 patients on
three occasions during the study, using questions
adapted from Morisky scale. Significant (p < 0.01) im-
provements were found in both groups at both 3 and 6
months post intervention, compared to before the I-MUR.
The greatest improvement in adherence occurred at 3
months post-intervention, with the improvement sus-
tained at 6 months (Fig. 3).
Correspondence analysis demonstrated that the patients
who achieved asthma control (ACT 20–25) were those
who did not miss or change their medication (Fig. 4).
Cost effectiveness analysis
At 3-months follow-up, only the difference in costs
(from the public healthcare and society perspectives)
were significant at the 0.01 level (Table 4). The bootstrap
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Fig. 2 Percentage of patients in group A and B with controlled asthma (ACT score ≥20) at four time points shown as both PP and ITT
Table 3 Changes in the number of active ingredients used by
patients before and after the I-MUR intervention
Before I-MUR 3 months after I-MUR 6 months after I-MUR
GA 5 (3–7) 4 (3–7) 4 (3–7)
GB 5 (3–7) 4 (2–7) 4 (3–7)
Values are presented as median (IQR)
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method was therefore employed to evaluate uncertainty
surrounding cost-effectiveness estimates.
In the economic analysis we have used mean rather
than median values, as this is more informative for plan-
ners of healthcare services. As the patient cost data were
skewed, the confidence limits around the means were
generated using non-parametric bootstrapping techniques.
The incremental cost-effectiveness plane (CEP) showed
60.50% of the plots falling into the south-east quadrant, in-
dicating that I-MUR service dominated the usual care op-
tion (less costly and more effective). Considering a WTP
threshold of €30,000 per additional QALY gained, the prob-
ability that I-MUR was more cost-effective is 71.50%. For
the secondary analysis, the incremental CEP showed about
half of the plots falling into the south-east quadrant. The
probability that I-MUR care was more cost-effective was
51.50% (Figs. 5 and 6). At 6 months, both the difference in
costs and utility were significant at 0.01 level. The majority
of plots in the cost-effectiveness scatter fell in the south-
east quadrant (between 82.70 and 69.60%; public healthcare
and society perspectives, respectively) and indicated that
usual care was dominated by I-MUR service. The probabil-
ity that I-MUR care was more cost-effective varied between
93.00 and 89.50%, respectively (Figs. 5 and 6).
At 9 months, both the difference in costs and utility
were significant at 0.01 level. The large majority of plots
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Fig. 3 Patients’ self-reported adherence to medications before and after I-MUR
Fig. 4 Relationship between asthma control and adherence to treatment after I-MUR
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Table 4 Costs and QALY estimates for the three scenarios considered in the cost-utility analysis
Intervention
(N = 600)
Control
(N = 663)
p-value
Mean Sd Mean Sd P
Scenario 1: 3 months
Difference in yearly patient costs between T3 and T0 (public healthcare perspective, [13] Euros 2015) −122.63 747.03 −113.29 828.04 0.01
Difference in yearly patient costs between T3 and T0 (societal perspective, [6] Euros 2015) −95.17 660.94 −95.82 741.32 0.01
Difference1 in QALYs between T3 and T0 [39] 0.02 0.10 0.01 0.10 0.86
Scenario 2: 6 months
Difference in yearly patient costs between T6 and T0 (public healthcare, [13] Euros 2015) −154.84 846.47 −113.29 828.04 0.01
Difference in yearly patient costs between T6 and T0 (societal perspective, [6] Euros 2015) −115.93 741.45 −95.82 741.32 0.01
Difference in QALY s between T6 and T0 [39] 0.03 0.12 0.01 0.10 0.01
Scenario 3: 9 months
Difference in yearly patient costs between T9 and T0 (public healthcare perspective, [13] Euros 2015) −207.04 828.88 −113.29 828.04 0.01
Difference in yearly patient costs between T9 and T0 (societal perspective [6] Euros 2015) −158.56 729.97 −96.12 741.37 0.01
Difference in QALYs between T9 and T0 [39] 0.04 0.11 0.01 0.10 0.01
Fig. 5 Cost Utility analysis (Italian public healthcare perspective, Euros 2015)
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in the cost-effectiveness scatter fell in the south-east
quadrant (between 98.10 and 93.60%; public healthcare
and society perspectives, respectively) and indicated that
usual care was dominated by I-MUR service. The prob-
ability of I-MUR being cost-effective was 100% (Figs. 5
and 6). Overall the probability of I-MUR care being
cost-effective doubled across time (from 51.50–71.50%
at 3 months up to 100% at 9 months).
Discussion
Main findings
The effectiveness analysis showed evidence for the su-
periority of I-MUR service compared with usual care for
patients with asthma in terms of the primary outcome of
ACT score and all of the secondary outcomes. There
was a statistically significant improvement in the propor-
tion of patients with controlled asthma in both groups
over the 9 months of follow-up and the median ACT score
moved from partial to good control after the I-MUR
intervention, at T3 in Group A and T6 in Group B.
The NNT was 10, thus indicating a potentially useful
intervention. Relatively few studies of pharmacist inter-
ventions report NNTs, however of those which do,
values are similar to that found here [46, 47].
The I-MUR intervention was shown to reduce the
number of active ingredients being used and to improve
patients’ adherence to their medications. In addition, a
clear link was demonstrated between adherence and ACT
score, suggesting that this may be one mechanism whereby
asthma control was improved. Adherence increased overall
by 35.4% 3 months post-intervention and by 40.0% at
6 months. The types of pharmaceutical care issues
identified by the pharmacists during the I-MUR were
primarily related to the need for education, monitoring
and potentially ineffective therapy. Hence the provision of
advice on use of medicines and how to optimise their ef-
fectiveness, together with frequent monitoring is likely to
be the mechanism whereby adherence and thus asthma
Fig. 6 Cost utitlity analysis (society perspective, Euros 2015)
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control were improved. The continuous improvement in
both asthma control and adherence in both groups sug-
gests that regular contact with the pharmacist and com-
pletion of the ACT score was in itself an important factor.
Cost-effectiveness analysis supported the hypothesis that
I-MUR is more cost effective than usual care and the prob-
ability of I-MUR being cost-effective doubled across time
(from 51.50% at 3 months to 100% at 9 months). Moreover
it was demonstrated that the key factor influencing asthma
control was adherence, which pharmacists are well placed
to influence, and the resultant improvements in both were
sustained over at least 6 months (9 months in Group A).
Comparison with other studies
Similar results have been found in RCTs of community
pharmacists’ intervention in asthma in other countries,
across Europe [27, 28], Australia [26] and North America
[22], with the largest studies to date being conducted in
Australia, Belgium and Spain [26–28]. One Australian
study [48] showed both improved adherence and improved
asthma control which was sustained for 12 months. The
Belgian study [27] assessed adherence through prescription
refill rates rather than patient completed questions, but also
assessed patient knowledge about asthma medication, but
showed no change in asthma control overall, only in a sub-
group of patients with uncontrolled asthma. While the
Spanish study [28] showed evidence of benefit, the work
was funded by a pharmaceutical company and one of the
patients’ inclusion criteria was the use of Budesonide/For-
moterol, a medication produced by the same company.
Other studies have also shown potential benefits of
pharmacist intervention in asthma, although many were
small and some were uncontrolled [29]. The English
MUR service, on which this intervention was based, has
relatively little evidence to support its effectiveness [49]
or cost effectiveness [50]. However one small, uncon-
trolled study has shown that the proportion of patients
with controlled asthma rose from 41 to 55% after receiv-
ing an MUR [51]. A systematic review of fee-for-service
pharmacist-led medication reviews in general showed
that this type of service improves adherence and clinical
markers in a range of conditions [52]. It is essential that
future studies should incorporate both clinical outcomes
and economic evaluations, to enable governments and
other commissioners to assess the potential benefits of
such services.
Strengths and limitations
This is the first study in Italy to evaluate a community
pharmacist-based intervention, and, to the best of our
knowledge, it appears to be the largest RCT of a com-
munity pharmacy intervention in asthma conducted in
any country in terms of the numbers of pharmacists and
patients. Further strengths are that it adopted the ACT
score as a measure of asthma control, as recommended
by GINA, which allowed measurement of both effective-
ness and cost-effectiveness (by translating ATC scores
into QALYs) of the novel I-MUR intervention. The large
number of pharmacists involved throughout the country
supports the generalisability of the results at national
level.
Standard practice in community pharmacy in Italy in-
volves little clinical input, being mainly a supply func-
tion, therefore the patients were unused to a pharmacist
taking an interest in their clinical status and providing
information about optimising medicines use, which may
have contributed to the effectiveness of the intervention.
The pharmacists providing the I-MUR were responsible
for both selecting patients and entering the data col-
lected onto the electronic template, possible sources of
bias. The population overall included more females than
males (p < 0.01) and, more importantly, the proportion
of patients not controlled differed between groups A and
B, with median ACT scores at baseline of 19 and 18. The
assessment of adherence did not use a validated tool, but
instead used only two patient-reported questions, in
the interests of brevity, which were similar to the ques-
tions used in the English MUR template. Also the initial
follow-up period before the usual care group received
the intervention was only 3 months. This meant that
we had to assume no change in ACT control from T3
onwards for the economic analysis. In addition it was
necessary to use secondary data rather than primary
data collection on cost and utility, which were derived
from different sources and were old estimates [6, 13],
actualised at 2015 [45].
Conclusion
This study demonstrates that the I-MUR service, which
is the first cognitive pharmaceutical service to be deliv-
ered in Italy, was both effective and cost-effective. The
Italian Government/Ministry of Health have since pro-
moted a change of community pharmacy practice, with
the I-MUR being the first nationally funded cognitive
pharmaceutical service in Italy [53]. The work has
therefore supported a significant cultural shift in Italian
community pharmacy practice, promoting the change
from a mainly logistic to a more patient-centred and
clinically-oriented role of the community pharmacist in
delivery of health care. Consideration is being given to
extending the service to other respiratory conditions,
but the successful service model applied here could en-
able community pharmacists in Italy to support the
care of patients with a wide range of long-term condi-
tions in the future. Moreover, it adds to the evidence
base world-wide demonstrating the potential effective-
ness and cost-effectiveness of community pharmacy
medication reviews.
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